Sep 18, 2023
|
CORAL GABLES, Fla. , Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that
|
Aug 16, 2023
|
Study Reveals LEMS Often Goes Undiagnosed in U.S. Patients with Small Cell Lung Cancer CORAL GABLES, Fla. , Aug. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
|
Aug 14, 2023
|
CORAL GABLES, Fla. , Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare
|
Aug 09, 2023
|
Achieved Record Q2 2023 Total Net Revenues of $99.6 Million Achieved FIRDAPSE ® 2023 Second Quarter Net Revenues of $64.9 Million , a 22% Increase YOY Achieved 2023 Second Quarter GAAP EPS Diluted of $0.33 Compared to $0.20 for Q2 2022 Achieved 2023 Second Quarter Non-GAAP EPS Diluted of $0.53
|
Jul 25, 2023
|
Mr. McEnany will Continue to Serve as Catalyst's Non-Executive Chairman of the Board Following his Retirement Nationally Recognized Executive Recruitment Firm has been Retained to Initiate Search CORAL GABLES, Fla. , July 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.
|
Jul 24, 2023
|
The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ET CORAL GABLES, Fla. , July 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and
|
Jul 19, 2023
|
Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy Synergistic Novel Asset Leverages Catalyst's Expertise and Bolsters Catalyst's Rare Neuroscience Portfolio Granted FDA Fast Track, Orphan Drug Designation, and a PDUFA Action
|
Jun 20, 2023
|
Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023 ) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan Drug Designation for Vamorolone to Treat Duchenne Muscular Dystrophy Catalyst Expects to Launch
|
Jun 01, 2023
|
Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million Forecasts FIRDAPSE ® 2023 Net Product Revenue Guidance of Between $245 Million and $255 Million , an Increase of 17% YoY Forecasts FYCOMPA ® 2023 Net Product Revenue of Approximately $130 Million for 11 Months
|
May 30, 2023
|
CORAL GABLES, Fla. , May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today
|